Gary Clark: Unfiltered
5 months ago
Xenon’s Epilepsy Data Signals a Market Shift Beyond Seizure Control
New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.
Read full article